This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsLungLife AI（9H4）株式概要診断会社であるLungLife AI, Inc.は、米国と中華人民共和国で人工知能（AI）技術を用いた肺がんの臨床診断ソリューションの研究開発を行っている。 詳細9H4 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬過去5年間の収益は年間7%増加しました。 リスク分析収益が 100 万ドル未満 ( $29K )意味のある時価総額がありません ( €2M )German市場と比較して、過去 3 か月間の株価の変動が非常に大きい最新の財務報告は6か月以上前のものである すべてのリスクチェックを見る9H4 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,860 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,860 investors already sharing narrativesYour Fair Value€Current Price€0.0351.0k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7m211k2016201920222025202620282031Revenue US$29.0kEarnings US$5.1kAdvancedSet Fair ValueView all narrativesLungLife AI, Inc. 競合他社MedigeneSymbol: DB:MDG1Market cap: €553.8kbioXXmedSymbol: DB:T5OMarket cap: €236.5kco.donSymbol: XTRA:CNWMarket cap: €6.5m4SCSymbol: DB:VSCMarket cap: €1.1m価格と性能株価の高値、安値、推移の概要LungLife AI過去の株価現在の株価UK£0.03552週高値UK£0.2152週安値UK£0.009ベータ0.371ヶ月の変化50.00%3ヶ月変化122.58%1年変化-83.09%3年間の変化-97.98%5年間の変化n/aIPOからの変化-98.49%最新ニュースお知らせ • Feb 03LungLife AI, Inc. to Seek Approval from the Shareholders to Cancel the Admission of the Company's Ordinary Shares to Trading on AIMLungLife AI, Inc. proposed to seek to reengage with parties regarding the securing of a strategic partner for LungLife. However, in light of the cash runway available to the Company and the lack of interest in a fundraising, it has now become clear to the Board that the most appropriate course of action is for the Board to seek approval from the shareholders of the Company to cancel the admission of the Company's ordinary shares to trading on AIM in accordance with Rule 41 of the AIM Rules for Companies. A circular convening a general meeting of the Company to approve the proposed cancellation and providing further detail on the next steps will be published in due course and a further announcement will be made at that time.お知らせ • Oct 27LungLife AI, Inc. Announces Resignation of James Mccullough as Non-Executive DirectorLungLife AI, Inc. announced the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024. James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc. Following this resignation, the Board remains confident in its current composition, which continues to reflect a strong balance of skills, experience, and independence. At this time, the Board has no immediate plans to seek a replacement, as it believes the current structure, together with the Scientific Advisory Board, is well-positioned to support the company's ongoing growth and development and does not impact the composition and independence of its committees.New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.23m market cap, or US$4.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).New Risk • Aug 23New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$4.3m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.70m market cap, or US$5.23m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Shareholders have been diluted in the past year (20% increase in shares outstanding).お知らせ • Aug 16LungLife AI Announces Medicare Finalises Coverage for Molecular Risk-Stratification Testing of Indeterminate Lung NodulesLungLife AI noted the publication of the finalized Local Coverage Determination (LCD) titled "Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy" (L39654), issued by the Medicare Administrative Contractor (MAC) Noridian Healthcare Solutions, LLC, which has jurisdiction over LungLife's California laboratory. The Medicare coverage criteria are effective for medical insurance claims with dates of service on or after September 22, 2024. This enables LungLife to apply for coverage under the LCD in order to receive payment from Medicare. This is a key step towards commercialisation for LungLife, having already received a billing code and established a price of $2,030 per LungLB® test. The new Medicare coverage policyestablishes criteria for molecular tests that aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules. This is crucial for healthcare providers and patients as setting out the circumstances under which Medicare will pay for these services removes a fundamental barrier to adoption by clinicians. Key points from the LCD include: Coverage for molecular tests to aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules who have a non-diagnostic bronchoscopy, provided the other enumerated coverage criteria of the LCDs are satisfied. LungLife will be eligible to submit a Technical Assessment for LungLB® under this LCD for post-bronchoscopy indications. Almost half1of bronchoscopy biopsies performed are not diagnostic and thus result in a need for follow up activities, accentuating the need for risk stratification testing like LungLB® in the post-bronchoscopy setting governed by the LCD. MolDX is currently considering additional evidence to expand the indications for coverage to pre-bronchoscopy risk stratification. This provides an additional opportunity for LungLife to seek coverage under a potential foundational LCD if they progress with this. Alternatively, LungLife would be in a position to seek an individual coverage determination for this area. Fundamental components for commercialisation: There are three fundamental reimbursement components for commercialisation of LungLB®: securing a designated billing code, establishing a price, and obtaining coverage. The company made strong progress across each of these as follows: A unique billing code allows LungLife to accurately bill for and receive reimbursement from insurance payers, including Medicare and private insurers. LungLife was assigned CPT code 0317U in January 2022. Medicare established a national price of $2,030 per test for LungLB®, effective in January 2023. Obtaining coverage from public and private payers is the next crucial step for LungLife. Following the publication of the LCD, it plan to submit a Technical Assessment for coverage under the LCD in order to receive payment from Medicare. This Foundational LCD provides a clear pathway for LungLife to pursue Medicare coverage with MolDX and is generally less time intensive than obtaining a new test specific LCD.お知らせ • Aug 15LungLife AI, Inc. to Report First Half, 2024 Results on Aug 22, 2024LungLife AI, Inc. announced that they will report first half, 2024 results on Aug 22, 2024最新情報をもっと見るRecent updatesお知らせ • Feb 03LungLife AI, Inc. to Seek Approval from the Shareholders to Cancel the Admission of the Company's Ordinary Shares to Trading on AIMLungLife AI, Inc. proposed to seek to reengage with parties regarding the securing of a strategic partner for LungLife. However, in light of the cash runway available to the Company and the lack of interest in a fundraising, it has now become clear to the Board that the most appropriate course of action is for the Board to seek approval from the shareholders of the Company to cancel the admission of the Company's ordinary shares to trading on AIM in accordance with Rule 41 of the AIM Rules for Companies. A circular convening a general meeting of the Company to approve the proposed cancellation and providing further detail on the next steps will be published in due course and a further announcement will be made at that time.お知らせ • Oct 27LungLife AI, Inc. Announces Resignation of James Mccullough as Non-Executive DirectorLungLife AI, Inc. announced the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024. James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc. Following this resignation, the Board remains confident in its current composition, which continues to reflect a strong balance of skills, experience, and independence. At this time, the Board has no immediate plans to seek a replacement, as it believes the current structure, together with the Scientific Advisory Board, is well-positioned to support the company's ongoing growth and development and does not impact the composition and independence of its committees.New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.23m market cap, or US$4.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).New Risk • Aug 23New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$4.3m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.70m market cap, or US$5.23m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Shareholders have been diluted in the past year (20% increase in shares outstanding).お知らせ • Aug 16LungLife AI Announces Medicare Finalises Coverage for Molecular Risk-Stratification Testing of Indeterminate Lung NodulesLungLife AI noted the publication of the finalized Local Coverage Determination (LCD) titled "Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy" (L39654), issued by the Medicare Administrative Contractor (MAC) Noridian Healthcare Solutions, LLC, which has jurisdiction over LungLife's California laboratory. The Medicare coverage criteria are effective for medical insurance claims with dates of service on or after September 22, 2024. This enables LungLife to apply for coverage under the LCD in order to receive payment from Medicare. This is a key step towards commercialisation for LungLife, having already received a billing code and established a price of $2,030 per LungLB® test. The new Medicare coverage policyestablishes criteria for molecular tests that aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules. This is crucial for healthcare providers and patients as setting out the circumstances under which Medicare will pay for these services removes a fundamental barrier to adoption by clinicians. Key points from the LCD include: Coverage for molecular tests to aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules who have a non-diagnostic bronchoscopy, provided the other enumerated coverage criteria of the LCDs are satisfied. LungLife will be eligible to submit a Technical Assessment for LungLB® under this LCD for post-bronchoscopy indications. Almost half1of bronchoscopy biopsies performed are not diagnostic and thus result in a need for follow up activities, accentuating the need for risk stratification testing like LungLB® in the post-bronchoscopy setting governed by the LCD. MolDX is currently considering additional evidence to expand the indications for coverage to pre-bronchoscopy risk stratification. This provides an additional opportunity for LungLife to seek coverage under a potential foundational LCD if they progress with this. Alternatively, LungLife would be in a position to seek an individual coverage determination for this area. Fundamental components for commercialisation: There are three fundamental reimbursement components for commercialisation of LungLB®: securing a designated billing code, establishing a price, and obtaining coverage. The company made strong progress across each of these as follows: A unique billing code allows LungLife to accurately bill for and receive reimbursement from insurance payers, including Medicare and private insurers. LungLife was assigned CPT code 0317U in January 2022. Medicare established a national price of $2,030 per test for LungLB®, effective in January 2023. Obtaining coverage from public and private payers is the next crucial step for LungLife. Following the publication of the LCD, it plan to submit a Technical Assessment for coverage under the LCD in order to receive payment from Medicare. This Foundational LCD provides a clear pathway for LungLife to pursue Medicare coverage with MolDX and is generally less time intensive than obtaining a new test specific LCD.お知らせ • Aug 15LungLife AI, Inc. to Report First Half, 2024 Results on Aug 22, 2024LungLife AI, Inc. announced that they will report first half, 2024 results on Aug 22, 2024Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Senior Independent Non-Executive Director Andy Boteler was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 26LungLife AI, Inc., Annual General Meeting, Jun 05, 2024LungLife AI, Inc., Annual General Meeting, Jun 05, 2024, at 15:00 Coordinated Universal Time. Location: Investec Bank plc, 30 Gresham Street, London United KingdomReported Earnings • Apr 05Full year 2023 earnings released: US$0.21 loss per share (vs US$0.30 loss in FY 2022)Full year 2023 results: US$0.21 loss per share (improved from US$0.30 loss in FY 2022). Net loss: US$5.41m (loss narrowed 29% from FY 2022). Revenue is forecast to grow 84% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany.Breakeven Date Change • Apr 04Forecast to breakeven in 2025The analyst covering LungLife AI expects the company to break even for the first time. New forecast suggests the company will make a profit of US$100.0k in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.お知らせ • Mar 27LungLife AI, Inc. to Report Fiscal Year 2023 Results on Apr 04, 2024LungLife AI, Inc. announced that they will report fiscal year 2023 results on Apr 04, 2024お知らせ • Mar 24LungLife AI, Inc. announced that it has received $0.31578 million in fundingLungLife AI, Inc. announced that it has received $315,780 in funding on March 22, 2024. The company issued common shares in the transaction. The company issued securities pursuant to exemption provided under Regulation D. The transaction included participation from eight investors.New Risk • Mar 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$37k revenue). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (US$4.2m net loss in 2 years). Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€10.5m market cap, or US$11.4m).お知らせ • Mar 05+ 1 more updateLungLife AI, Inc. has filed a Follow-on Equity Offering in the amount of £1.81 million.LungLife AI, Inc. has filed a Follow-on Equity Offering in the amount of £1.81 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,457,143 Price\Range: £0.35 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 714,286 Price\Range: £0.35 Transaction Features: Regulation S; Subsequent Direct ListingNew Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$37k revenue). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (US$4.2m net loss in 2 years). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€12.8m market cap, or US$13.9m).Reported Earnings • Aug 09First half 2023 earnings released: US$0.11 loss per share (vs US$0.17 loss in 1H 2022)First half 2023 results: US$0.11 loss per share (improved from US$0.17 loss in 1H 2022). Net loss: US$2.81m (loss narrowed 37% from 1H 2022). Revenue is forecast to grow 100% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Germany.お知らせ • Aug 03LungLife AI, Inc. to Report First Half, 2023 Results on Aug 08, 2023LungLife AI, Inc. announced that they will report first half, 2023 results on Aug 08, 2023株主還元9H4DE BiotechsDE 市場7D0%-4.6%0.9%1Y-83.1%5.2%3.9%株主還元を見る業界別リターン: 9H4過去 1 年間で5.2 % の収益を上げたGerman Biotechs業界を下回りました。リターン対市場: 9H4は、過去 1 年間で3.9 % のリターンを上げたGerman市場を下回りました。価格変動Is 9H4's price volatile compared to industry and market?9H4 volatility9H4 Average Weekly Movement93.5%Biotechs Industry Average Movement6.8%Market Average Movement5.3%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: 9H4の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 9H4の 週次ボラティリティ は、過去 1 年間で49%から94%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト20098Paul Paganolunglifeai.com診断会社であるLungLife AI, Inc.は、米国と中華人民共和国で人工知能（AI）技術を用いた肺がんの臨床診断ソリューションの研究開発を行っている。同社は、CTスキャンで確認された肺結節のがん・良性を層別化する血液ベースの検査法LungLBの開発に取り組んでいる。同社は以前はCynvenio Biosystems, Inc.として知られていたが、2019年5月にLungLife AI, Inc.に社名を変更した。LungLife AI, Inc.は2009年に法人化され、カリフォルニア州サウザンドオークスを拠点としている。もっと見るLungLife AI, Inc. 基礎のまとめLungLife AI の収益と売上を時価総額と比較するとどうか。9H4 基礎統計学時価総額€1.51m収益（TTM）-€3.93m売上高(TTM)€25.51k59.2xP/Sレシオ-0.4xPER（株価収益率9H4 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計9H4 損益計算書（TTM）収益US$29.00k売上原価US$0売上総利益US$29.00kその他の費用US$4.50m収益-US$4.47m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）-0.15グロス・マージン100.00%純利益率-15,403.45%有利子負債／自己資本比率0%9H4 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/05/30 15:33終値2025/05/28 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LungLife AI, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Adam BarkerGoodbody StockbrokersZoe KaramanoliGoodbody Stockbrokers
お知らせ • Feb 03LungLife AI, Inc. to Seek Approval from the Shareholders to Cancel the Admission of the Company's Ordinary Shares to Trading on AIMLungLife AI, Inc. proposed to seek to reengage with parties regarding the securing of a strategic partner for LungLife. However, in light of the cash runway available to the Company and the lack of interest in a fundraising, it has now become clear to the Board that the most appropriate course of action is for the Board to seek approval from the shareholders of the Company to cancel the admission of the Company's ordinary shares to trading on AIM in accordance with Rule 41 of the AIM Rules for Companies. A circular convening a general meeting of the Company to approve the proposed cancellation and providing further detail on the next steps will be published in due course and a further announcement will be made at that time.
お知らせ • Oct 27LungLife AI, Inc. Announces Resignation of James Mccullough as Non-Executive DirectorLungLife AI, Inc. announced the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024. James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc. Following this resignation, the Board remains confident in its current composition, which continues to reflect a strong balance of skills, experience, and independence. At this time, the Board has no immediate plans to seek a replacement, as it believes the current structure, together with the Scientific Advisory Board, is well-positioned to support the company's ongoing growth and development and does not impact the composition and independence of its committees.
New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.23m market cap, or US$4.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).
New Risk • Aug 23New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$4.3m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.70m market cap, or US$5.23m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Shareholders have been diluted in the past year (20% increase in shares outstanding).
お知らせ • Aug 16LungLife AI Announces Medicare Finalises Coverage for Molecular Risk-Stratification Testing of Indeterminate Lung NodulesLungLife AI noted the publication of the finalized Local Coverage Determination (LCD) titled "Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy" (L39654), issued by the Medicare Administrative Contractor (MAC) Noridian Healthcare Solutions, LLC, which has jurisdiction over LungLife's California laboratory. The Medicare coverage criteria are effective for medical insurance claims with dates of service on or after September 22, 2024. This enables LungLife to apply for coverage under the LCD in order to receive payment from Medicare. This is a key step towards commercialisation for LungLife, having already received a billing code and established a price of $2,030 per LungLB® test. The new Medicare coverage policyestablishes criteria for molecular tests that aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules. This is crucial for healthcare providers and patients as setting out the circumstances under which Medicare will pay for these services removes a fundamental barrier to adoption by clinicians. Key points from the LCD include: Coverage for molecular tests to aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules who have a non-diagnostic bronchoscopy, provided the other enumerated coverage criteria of the LCDs are satisfied. LungLife will be eligible to submit a Technical Assessment for LungLB® under this LCD for post-bronchoscopy indications. Almost half1of bronchoscopy biopsies performed are not diagnostic and thus result in a need for follow up activities, accentuating the need for risk stratification testing like LungLB® in the post-bronchoscopy setting governed by the LCD. MolDX is currently considering additional evidence to expand the indications for coverage to pre-bronchoscopy risk stratification. This provides an additional opportunity for LungLife to seek coverage under a potential foundational LCD if they progress with this. Alternatively, LungLife would be in a position to seek an individual coverage determination for this area. Fundamental components for commercialisation: There are three fundamental reimbursement components for commercialisation of LungLB®: securing a designated billing code, establishing a price, and obtaining coverage. The company made strong progress across each of these as follows: A unique billing code allows LungLife to accurately bill for and receive reimbursement from insurance payers, including Medicare and private insurers. LungLife was assigned CPT code 0317U in January 2022. Medicare established a national price of $2,030 per test for LungLB®, effective in January 2023. Obtaining coverage from public and private payers is the next crucial step for LungLife. Following the publication of the LCD, it plan to submit a Technical Assessment for coverage under the LCD in order to receive payment from Medicare. This Foundational LCD provides a clear pathway for LungLife to pursue Medicare coverage with MolDX and is generally less time intensive than obtaining a new test specific LCD.
お知らせ • Aug 15LungLife AI, Inc. to Report First Half, 2024 Results on Aug 22, 2024LungLife AI, Inc. announced that they will report first half, 2024 results on Aug 22, 2024
お知らせ • Feb 03LungLife AI, Inc. to Seek Approval from the Shareholders to Cancel the Admission of the Company's Ordinary Shares to Trading on AIMLungLife AI, Inc. proposed to seek to reengage with parties regarding the securing of a strategic partner for LungLife. However, in light of the cash runway available to the Company and the lack of interest in a fundraising, it has now become clear to the Board that the most appropriate course of action is for the Board to seek approval from the shareholders of the Company to cancel the admission of the Company's ordinary shares to trading on AIM in accordance with Rule 41 of the AIM Rules for Companies. A circular convening a general meeting of the Company to approve the proposed cancellation and providing further detail on the next steps will be published in due course and a further announcement will be made at that time.
お知らせ • Oct 27LungLife AI, Inc. Announces Resignation of James Mccullough as Non-Executive DirectorLungLife AI, Inc. announced the resignation of James McCullough, as a non-executive director of the company, with effect from 24 October 2024. James McCullough has taken the decision to step down from the Board to focus on his Executive role at Renalytix plc. Following this resignation, the Board remains confident in its current composition, which continues to reflect a strong balance of skills, experience, and independence. At this time, the Board has no immediate plans to seek a replacement, as it believes the current structure, together with the Scientific Advisory Board, is well-positioned to support the company's ongoing growth and development and does not impact the composition and independence of its committees.
New Risk • Oct 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.23m market cap, or US$4.68m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding).
New Risk • Aug 23New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -US$4.3m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (US$29k revenue). Market cap is less than US$10m (€4.70m market cap, or US$5.23m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-US$4.3m). Shareholders have been diluted in the past year (20% increase in shares outstanding).
お知らせ • Aug 16LungLife AI Announces Medicare Finalises Coverage for Molecular Risk-Stratification Testing of Indeterminate Lung NodulesLungLife AI noted the publication of the finalized Local Coverage Determination (LCD) titled "Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy" (L39654), issued by the Medicare Administrative Contractor (MAC) Noridian Healthcare Solutions, LLC, which has jurisdiction over LungLife's California laboratory. The Medicare coverage criteria are effective for medical insurance claims with dates of service on or after September 22, 2024. This enables LungLife to apply for coverage under the LCD in order to receive payment from Medicare. This is a key step towards commercialisation for LungLife, having already received a billing code and established a price of $2,030 per LungLB® test. The new Medicare coverage policyestablishes criteria for molecular tests that aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules. This is crucial for healthcare providers and patients as setting out the circumstances under which Medicare will pay for these services removes a fundamental barrier to adoption by clinicians. Key points from the LCD include: Coverage for molecular tests to aid in the diagnosis of lung cancer in patients with indeterminate pulmonary (lung) nodules who have a non-diagnostic bronchoscopy, provided the other enumerated coverage criteria of the LCDs are satisfied. LungLife will be eligible to submit a Technical Assessment for LungLB® under this LCD for post-bronchoscopy indications. Almost half1of bronchoscopy biopsies performed are not diagnostic and thus result in a need for follow up activities, accentuating the need for risk stratification testing like LungLB® in the post-bronchoscopy setting governed by the LCD. MolDX is currently considering additional evidence to expand the indications for coverage to pre-bronchoscopy risk stratification. This provides an additional opportunity for LungLife to seek coverage under a potential foundational LCD if they progress with this. Alternatively, LungLife would be in a position to seek an individual coverage determination for this area. Fundamental components for commercialisation: There are three fundamental reimbursement components for commercialisation of LungLB®: securing a designated billing code, establishing a price, and obtaining coverage. The company made strong progress across each of these as follows: A unique billing code allows LungLife to accurately bill for and receive reimbursement from insurance payers, including Medicare and private insurers. LungLife was assigned CPT code 0317U in January 2022. Medicare established a national price of $2,030 per test for LungLB®, effective in January 2023. Obtaining coverage from public and private payers is the next crucial step for LungLife. Following the publication of the LCD, it plan to submit a Technical Assessment for coverage under the LCD in order to receive payment from Medicare. This Foundational LCD provides a clear pathway for LungLife to pursue Medicare coverage with MolDX and is generally less time intensive than obtaining a new test specific LCD.
お知らせ • Aug 15LungLife AI, Inc. to Report First Half, 2024 Results on Aug 22, 2024LungLife AI, Inc. announced that they will report first half, 2024 results on Aug 22, 2024
Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Senior Independent Non-Executive Director Andy Boteler was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 26LungLife AI, Inc., Annual General Meeting, Jun 05, 2024LungLife AI, Inc., Annual General Meeting, Jun 05, 2024, at 15:00 Coordinated Universal Time. Location: Investec Bank plc, 30 Gresham Street, London United Kingdom
Reported Earnings • Apr 05Full year 2023 earnings released: US$0.21 loss per share (vs US$0.30 loss in FY 2022)Full year 2023 results: US$0.21 loss per share (improved from US$0.30 loss in FY 2022). Net loss: US$5.41m (loss narrowed 29% from FY 2022). Revenue is forecast to grow 84% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Germany.
Breakeven Date Change • Apr 04Forecast to breakeven in 2025The analyst covering LungLife AI expects the company to break even for the first time. New forecast suggests the company will make a profit of US$100.0k in 2025. Average annual earnings growth of 78% is required to achieve expected profit on schedule.
お知らせ • Mar 27LungLife AI, Inc. to Report Fiscal Year 2023 Results on Apr 04, 2024LungLife AI, Inc. announced that they will report fiscal year 2023 results on Apr 04, 2024
お知らせ • Mar 24LungLife AI, Inc. announced that it has received $0.31578 million in fundingLungLife AI, Inc. announced that it has received $315,780 in funding on March 22, 2024. The company issued common shares in the transaction. The company issued securities pursuant to exemption provided under Regulation D. The transaction included participation from eight investors.
New Risk • Mar 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$37k revenue). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (US$4.2m net loss in 2 years). Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€10.5m market cap, or US$11.4m).
お知らせ • Mar 05+ 1 more updateLungLife AI, Inc. has filed a Follow-on Equity Offering in the amount of £1.81 million.LungLife AI, Inc. has filed a Follow-on Equity Offering in the amount of £1.81 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,457,143 Price\Range: £0.35 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 714,286 Price\Range: £0.35 Transaction Features: Regulation S; Subsequent Direct Listing
New Risk • Feb 24New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$37k revenue). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (US$4.2m net loss in 2 years). Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€12.8m market cap, or US$13.9m).
Reported Earnings • Aug 09First half 2023 earnings released: US$0.11 loss per share (vs US$0.17 loss in 1H 2022)First half 2023 results: US$0.11 loss per share (improved from US$0.17 loss in 1H 2022). Net loss: US$2.81m (loss narrowed 37% from 1H 2022). Revenue is forecast to grow 100% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Germany.
お知らせ • Aug 03LungLife AI, Inc. to Report First Half, 2023 Results on Aug 08, 2023LungLife AI, Inc. announced that they will report first half, 2023 results on Aug 08, 2023
